Seaport and Hemab price IPOs as Avalyn soars on Nasdaq debut

Three biotechnology companies announced the pricing of their initial public offerings between Thursday and Friday, collectively targeting more than $850 million in proceeds.

Seaport Therapeutics and Hemab Therapeutics each set their IPO prices, preparing for their upcoming market debuts. The pricing details were disclosed in filings but specific share counts and pricing ranges were not provided in the source.

Avalyn Pharma saw its shares jump sharply after the pricing announcement, reflecting strong investor interest as the company prepares to begin trading on the Nasdaq exchange.

The trio of offerings adds significant new capital to the biotech sector, highlighting continued investor appetite for early‑stage pharmaceutical development.